Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia

Blood

Volumn 118, Issue 10, 2011, Pages 2821-2826

  Maurer, Matthew J ^a   Cerhan, James R ^a   Katzmann, Jerry A ^a   Link, Brian K ^b   Allmer, Cristine ^a   Zent, Clive S ^a   Call, Timothy G ^a   Rabe, Kari G ^a   Hanson, Curtis A ^a   Kay, Neil E ^a   Slager, Susan L ^a   Witzig, Thomas E ^a   Shanafelt, Tait D ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL FREE LIGHT CHAIN PARAPROTEIN; PARAPROTEIN; POLYCLONAL FREE LIGHT CHAIN PARAPROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PROTEIN DISORDER; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FREE LIGHT CHAIN PARAPROTEIN ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

EID: 80052648801     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-349134     Document Type: Article

References (26)

1. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47(4):673-680. (Pubitemid 32275810)
2. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812-817. (Pubitemid 41076419)
3. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111(2):785-789.
4. Dingli D, Kyle RA, Rajkumar SV, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood. 2006;108(6):1979-1983. (Pubitemid 44395010)
5. Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010;116(24):5126-5129.
6. Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1684-1690.
7. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free {kappa} and free {lambda} immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48(9):1437-1444. (Pubitemid 34925779)
8. Gottenberg J-E, Aucouturier F, Goetz J, et al. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjögren's syndrome. Ann Rheum Dis. 2007;66(1):23-27. (Pubitemid 46044856)
9. Van der Heijden M, Kraneveld A, Redegeld F. Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur J Pharmacol. 2006;533(1-3):319-326. (Pubitemid 43340023)
10. Maino VC, Kurnick JT, Kubo RT, Grey HM. Mitogen activation of human chronic lymphatic leukemia cells. J Immunol. 1977;118(3):742-748.
11. Gordon J, Howlett AR, Smith JL. Free light chain synthesis by neoplastic cells in chronic lymphocytic leukaemia and non-Hodkgin's lymphoma. Immunology. 1978;34(3):397-404. (Pubitemid 8292916)
12. Hannam-Harris A, Gordon J, Smith J. Immunoglobulin synthesis by neoplastic B lymphocytes: free light chain synthesis as a marker of B cell differentiation. J Immunol. 1980;125(5):2177-2181. (Pubitemid 10022962)
13. Deegan M, Abraham J, Sawdyk M, Van Slyck E. High incidence of monoclonal proteins in the serum and urine of chronic lymphocytic leukemia patients. Blood. 1984;64(6):1207-1211. (Pubitemid 15224531)
14. Martin W, Abraham R, Shanafelt T, et al. Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Transl Res. 2007;149(4):231-235. (Pubitemid 46442009)
15. Pratt G, Harding S, Holder R, et al. Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. Br J Haematol. 2009;144(2):217-222.
16. Yegin ZA, Özkurt ZN, Yaǧci M. Free light chain: a novel predictor of adverse outcome in chronic lymphocytic leukemia. Eur J Haematol. 2010;84(5):406-411.
17. Shanafelt TD, Drake MT, Maurer MJ, et al. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood. 2011;117(5):1492-1498.
18. Cheson B, Bennett J, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997. (Pubitemid 26189840)
19. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17(12):3835-3849.
20. Jelinek DF, Tschumper RC, Geyer SM, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol. 2001;115(4):854-861. (Pubitemid 34042903)
21. Dewald GW, Brockman SR, Paternoster SF, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol. 2003;121(2):287-295. (Pubitemid 36560596)
22. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006;24(28):4634-4641. (Pubitemid 46630962)
23. Maurer MJ, Micallef INM, Cerhan JR, et al. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol. 2011;29(12):1620-1626.
24. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics. 2005;61(1):92-105. (Pubitemid 40380968)
25. Shanafelt TD, Jenkins G, Call TG, et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer. 2009;115(2):363-372.
26. Dispenzieri A, Kyle R, Katzmann JA, et al. Nonclonal serum immunoglobulin free light chains (FLC) as markers of overall survival [abstract]. Blood. 2010;116(21):Abstract 3893.